002099 海翔药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.687-7.1721.4401.5925.520
总资产报酬率 ROA (%)0.503-5.2791.0721.2534.592
投入资产回报率 ROIC (%)0.559-5.8431.1771.3614.823

边际利润分析
销售毛利率 (%)28.13014.02726.63637.24345.423
营业利润率 (%)3.389-21.3754.0464.91215.994
息税前利润/营业总收入 (%)1.642-22.908-0.0625.76417.314
净利润/营业总收入 (%)3.535-19.4113.1833.77812.936

收益指标分析
经营活动净收益/利润总额(%)209.56334.630226.02495.789102.100
价值变动净收益/利润总额(%)-0.81925.229-41.9997.966-5.160
营业外收支净额/利润总额(%)3.5460.425-8.5270.804-0.447

偿债能力分析
流动比率 (X)1.4231.4531.6471.9842.742
速动比率 (X)1.0601.0651.0881.4602.126
资产负债率 (%)28.10625.51027.26323.77018.479
带息债务/全部投入资本 (%)18.33115.74317.30814.636--
股东权益/带息债务 (%)437.640524.765464.876567.126921.992
股东权益/负债合计 (%)256.080292.245266.936320.775441.168
利息保障倍数 (X)-0.87815.8870.0167.09012.442

营运能力分析
应收账款周转天数 (天)77.67476.54465.76864.8240.000
存货周转天数 (天)171.935173.972182.408188.7720.000